Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia

Overview of attention for article published in eJHaem, May 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 407 followers.

RT @malignantheme: Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halte…

Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halted. A tough reminder of the challenges in translating early hope into clinical success. #AML https://t.co/RRGbYHjakf

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.